MedTrace Logo

Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV

NCT00313287 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2017-02-01

No results posted yet for this study

Summary

The purpose of this study is to determine safety and efficacy of 30 mg daily dose of clevudine (L-FMAU) at 24 weeks of treatment in patients with chronic HBV.

Conditions

Interventions

DRUG

clevudine

Sponsors & Collaborators

  • Bukwang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Hyo-Suk Lee, MD. PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2004-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00313287 on ClinicalTrials.gov